Further Information: http://www.rxipharma.com
RXi Acquires Exclusive License to Potentially Paradigm-Changing RNAi Delivery Technology from Advirna LLC The in-licensed technologies encompass four distinct approaches, with the primary focus on “self-delivery” of RNAi therapeutics.
RXi Pharmaceuticals Presented Breakthrough RNAi Delivery Technologies at the TIDES® 2009 Conference Company’s CSO, Anastasia Khvorova, presented new pre-clinical data on therapeutically advanced RNAi compounds and delivery technologies.
RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts Company plans to advance the discovery and development Oral rxRNA™ therapeutics for inflammatory diseases.
RXi Licenses Rights to RNAi Sequences to Genes for Therapeutic Applications from Thermo Scientific RXi exclusively licenses certain RNAi sequences to an undisclosed number of target genes for the ongoing development of its rxRNA™ compounds.
